Phase 3 Randomized Clinical Trial Evaluating the Safety of Reproxalap in Patients With Dry Eye Disease
Authors:
Open Access
- 11 April 2026
- journal article
- Published by Springer Nature in Ophthalmology and Therapy
- Vol. 15 (5) , 1807-1821
Abstract
Reactive aldehyde species (RASP) are proinflammatory molecules that have been implicated in ocular inflammatory diseases, including dry eye disease (DED). Reproxalap is a small molecule RASP inhibitor in development for the treatment of DED. The objective of this clinical trial was to evaluate the long-term safety of reproxalap 0.25% ophthalmic solution compared with vehicle in patients with DED. This was a phase 3, multicenter, double-masked, randomized, vehicle-controlled, parallel-group safety clinical trial in patients with DED. Eligible patients were randomized 2:1 to bilateral treatment with reproxalap or vehicle for 6 weeks or 12 months, with the treatment administered four times daily (QID) for the first 4 weeks then twice daily (BID) for either 2 weeks or 11 months. Safety assessments included treatment-emergent adverse events (TEAEs), slit-lamp biomicroscopy, dilated fundoscopy, best-corrected visual acuity (BCVA), intraocular pressure, corneal endothelial cell density, and laboratory assessments. The primary endpoint was the occurrence of treatment-related serious ocular TEAEs. A total of 757 patients were enrolled and treated with reproxalap (n = 504) or vehicle (n = 253). In the 12-month arms, 111 and 72 patients receiving reproxalap and vehicle, respectively, completed the trial. There were no treatment-related serious TEAEs. The most common TEAE in reproxalap-treated patients was transient, mild, instillation site irritation, most commonly lasting < 1 min. Other ocular TEAEs were similar between reproxalap and vehicle. No safety concerns were identified. Post hoc analysis of BCVA change from baseline in the 12-month safety population showed larger BCVA improvement over 12 months with reproxalap compared with vehicle (p = 0.0185). The results support the safety of long-term topical reproxalap therapy in patients with DED. ClinicalTrials.gov identifier NCT04735393.Keywords
Funding Information
- AbbVie
- Aldeyra Therapeutics
This publication has 21 references indexed in Scilit:
- Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye DiseaseOphthalmology, 2025
- Reproxalap Improves Ocular Redness, Tear Production, and Symptoms in a Pivotal Dry Eye Disease Chamber TrialOphthalmology Science, 2025
- Real-World Experience with Lifitegrast Ophthalmic Solution in Patients with Dry Eye Disease: A Provider Survey in the USA and CanadaOphthalmology and Therapy, 2025
- Quintessence of currently approved and upcoming treatments for dry eye diseaseGraefe's Archive for Clinical and Experimental Ophthalmology, 2024
- Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye DiseaseAmerican Journal of Ophthalmology, 2021
- Estimated Prevalence and Incidence of Dry Eye Disease Based on Coding Analysis of a Large, All-age United States Health Care SystemAmerican Journal of Ophthalmology, 2019
- Lifitegrast for the Treatment of Dry Eye DiseaseOphthalmology, 2017
- Lifitegrast Ophthalmic Solution 5.0% versus Placebo for Treatment of Dry Eye DiseaseOphthalmology, 2015
- Lifitegrast Ophthalmic Solution 5.0% for Treatment of Dry Eye DiseaseOphthalmology, 2014
- Reliability and Validity of the Ocular Surface Disease IndexArchives of Ophthalmology (1950), 2000